Welcome to our dedicated page for Biocorrx news (Ticker: BICX), a resource for investors and traders seeking the latest updates and insights on Biocorrx stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biocorrx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biocorrx's position in the market.
BioCorRx (OTCQB: BICX) has submitted an Investigational New Drug (IND) application to the FDA for BICX104, a naltrexone pellet implant aimed at treating Opioid Use Disorder (OUD). This biodegradable pellet, developed with NIH support, has progressed through nonclinical studies and received FDA approval for the 505(b)(2) regulatory pathway, potentially expediting its approval. The opioid crisis has worsened during the pandemic, heightening the urgency for effective treatments. The company aims to address this growing issue through its innovative medical solutions.
BioCorRx Inc. (OTCQB: BICX) provided a year-end update for 2020, highlighting significant corporate progress despite challenges posed by the COVID-19 pandemic. The company’s subsidiary advanced pivotal GLP preclinical studies for a sustained release naltrexone implant aimed at treating opioid and alcohol use disorders. They secured an additional $2.8 million grant from NIDA, enhancing their financial foundation for FDA application. A recent private placement raised $2.25 million, validating their business strategy. The company anticipates initiating human studies in 2021.
BioCorRx Inc. (OTCQB: BICX) has completed a private placement, issuing 1.125 million shares at $2.00 each, raising $2.25 million. The funding will further develop its addiction treatment pipeline, including the sustained release naltrexone implant aimed at opioid and alcohol use disorders. The Company is preparing an IND application for FDA submission with hopes of commencing human studies this year. CEO Lourdes Felix emphasizes that this investment validates their strategy and growth potential, aiming to create significant shareholder value.
BioCorRx Inc. (OTCQB: BICX) announced the appointment of Joseph J. Galligan to its Board of Directors, effective February 24, 2021. Galligan has extensive experience in capital markets, having served as a senior advisor to BioCorRx since April 2019 and has held notable positions at DoubleLine Capital and The TCW Group. CEO Lourdes Felix emphasized Galligan's invaluable leadership as the company aims for business development and a potential Nasdaq listing.
BioCorRx (OTCQB: BICX) announced a partnership with Truusight Health to provide their Beat Addiction Recovery program to self-funded health plans. This program combines medication-assisted treatment with cognitive-behavioral therapy and peer support, enhancing access to addiction care, especially amid rising opioid-related deaths. The program's name change aligns with the launch of a new website, www.BeatAddiction.com, offering expanded options. CEO Brady Granier emphasized the need for comprehensive care during the COVID-19 pandemic.